Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01677910
Study type Interventional
Source Lexicon Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date January 8, 2013
Completion date March 21, 2016

See also
  Status Clinical Trial Phase
Recruiting NCT04993261 - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors Early Phase 1
Not yet recruiting NCT04039516 - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Phase 2
Completed NCT01234168 - A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Terminated NCT04073017 - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency N/A
Recruiting NCT05756608 - Fibrosis in Chronic and Delayed Myocardial Infarction
Completed NCT00774930 - An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Phase 3
Withdrawn NCT04713202 - Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl Phase 2
Completed NCT00853047 - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Phase 2
Completed NCT02063659 - Telotristat Etiprate for Carcinoid Syndrome Therapy Phase 3
Withdrawn NCT04776876 - Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Phase 2
Completed NCT03223428 - Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Recruiting NCT03453489 - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Phase 2
Active, not recruiting NCT05361668 - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Phase 2
Completed NCT01104415 - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Phase 2
Withdrawn NCT01172717 - Study of Panitumumab in the Treatment of Carcinoid Syndrome Phase 2
Terminated NCT00884715 - Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Phase 1/Phase 2
Completed NCT01430871 - Effects of Serotonin Excess on Bone in Carcinoid Syndrome N/A
Completed NCT02026063 - Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Phase 3
Terminated NCT01018953 - Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Phase 2
Terminated NCT04140409 - Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation Phase 4